PD-1/PD-L1 inhibitors

• US 10,710,986 B2
• Filed: 02/12/2019
• Issued: 07/14/2020
• Est. Priority Date: 02/13/2018
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Aktoudianakis, Evangelos, Cho, Aesop, Du, Zhimin, Graupe, Michael, Lad, Lateshkumar Thakorlal, Machicao Tello, Paulo A., Medley, Jonathan William, Metobo, Samuel E., Mukherjee, Prasenjit Kumar, Naduthambi, Devan, Parkhill, Eric Q., Phillips, Barton W., Simonovich, Scott Preston, Squires, Neil H., Wang, Peiyuan, Watkins, William J., Xu, Jie, Yang, Kin Shing, Ziebenhaus, Christopher Allen
• Primary Examiner(s): Sznaidman, Marcos L
• Application Number:
  US16/274,106
• Publication Number:
  US 20190270727A1
• Time in Patent Office: 518 Days
• Field of Search: 514247
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/497 containing further heterocyclic rings
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07D 241/18 Oxygen or sulfur atoms
• CPC Class Codes: C07D 241/20 Nitrogen atoms nitro radicals C07D241/16
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 487/08 Bridged systems
• CPC Class Codes: C07D 487/10 Spiro-condensed systems
• CPC Class Codes: C07D 491/107 with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86

Abstract

Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Claims

1. A compound which is:

2. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2, further comprising one or more additional therapeutic agents.

4. The pharmaceutical composition of claim 3, wherein the additional therapeutic agent is an anticancer agent selected from nivolumab, pembrolizumab, atezolizumab, and ipilimumab.

5. A method for treating hepatitis B virus comprising administering a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.